BioSpace News Archive

Forge Biologics Announces Nine Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting.

Aurion Biotech today announced that it has completed dosing of all subjects in its Phase 1 / 2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Enanta Pharmaceuticals, Inc. announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals’ Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta’s new Chief Legal Officer.

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, and Debiopharm, a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC clinical trial investigating lunresertib in combination with Debio 0123.

Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced it will host a virtual KOL event on Wednesday, May 8, 2024 at 10:00 AM ET.

Nautilus Biotechnology, Inc., a company pioneering a single molecule proteome analysis platform, reported financial results for the first quarter ended March 31, 2024.

Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tuesday May 7, 2024.

Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced an Independent Safety Committee approved an increase in dosing to 4,000mg over a fast infusion of 30 minutes in a Phase I/II trial evaluating its lead candidate, RECCE® 327 (R327).

Sutro Biopharma, Inc. today announced that the randomized portion (Part 2) of REFRαME-O1, the registration-directed trial of luveltamab tazevibulin (luvelta) in platinum-resistant ovarian cancer (PROC), is now open for enrollment, and the planned 50 patients in Part 1 of the trial have been enrolled.

Alumis Inc. today announced that dosing has commenced in a Phase 1 clinical trial of A-005 in healthy participants.